Fundraising Fox

Northwest Biotherapeutics

OTC: NWBO

Bethesda, US · Delaware corporation · 2 known investors

Northwest Biotherapeutics is a clinical-stage biotechnology company developing personalized cancer vaccines, marketed under the DCVax platform, that use activated dendritic cells to treat a range of solid tumor cancers. Its product lines include DCVax-L, DCVax-Direct, and DCVax-Prostate.

Founders & leadership

AB
Alton BoyntonFounder
LF
Linda F PowersExecutive
MBMarnix Bosch
Marnix BoschExecutive
LG
Leslie GoldmanExecutive
LP
Linda PowersinCEOformer

Board

NM
Navid MalikBoard director
JJ
Jerry JasinowskiBoard director
JC
J Cofer BlackBoard director

Investors · 2

Reported raises · per SEC filings

Form D private placements

$10.9M disclosed across 3 of 5 rounds · 2016–2026

$2.6MofferedSep 2020 · 2 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Jerry J JasinowskiDirector
  • Leslie J GoldmanExecutive Officer
  • J Cofer BlackDirector
  • Navid MalikDirector
  • Alton BoyntonExecutive Officer, Director
  • Marnix L BoschExecutive Officer
  • Linda F PowersExecutive Officer, Director
Offering amount
$2.6M
First sale
Aug 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$880KraisedJan 2018 · Biotechnology
Rule 506(c)
Officers, directors & promoters on the filing
  • Linda F PowersExecutive Officer, Director
  • Navid MalikDirector
  • Marnix BoschExecutive Officer
  • Jerry JasinowskiDirector
  • Leslie GoldmanExecutive Officer
  • J Cofer BlackDirector
  • Alton L BoyntonExecutive Officer, Director
Amount sold
$880K
Minimum investment
$10K
First sale
Dec 2017
Incorporated
Corporation, Delaware
Federal exemptions
06c
Full filing on SEC EDGAR ↗
$52KraisedMay 2017 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • J Cofer BlackDirector
  • Robert A FarmerDirector
  • Jerry JasinowskiDirector
  • Navid MalikDirector
  • Leslie GoldmanExecutive Officer
  • Alton L BoyntonExecutive Officer, Director
  • Linda F PowersExecutive Officer, Director
Amount sold
$52K
First sale
May 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$10MraisedMar 2016 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Cofer BlackDirector
  • Navid MalikDirector
  • Alton L. BoyntonExecutive Officer, Director
  • Susan BayhDirector
  • Linda F. PowersExecutive Officer, Director
  • Jerry JasinowskiDirector
  • Robert A. FarmerDirector
Offering amount
$10M
Amount sold
$10M
Minimum investment
$595.4K
Sales commissions
$700K
Placement agents
H.C. Wainwright
First sale
Feb 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 3

by search overlap

Companies competing with Northwest Biotherapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Frequently asked questions

What does Northwest Biotherapeutics do?
Northwest Biotherapeutics is a clinical-stage biotechnology company developing personalized cancer vaccines, marketed under the DCVax platform, that use activated dendritic cells to treat a range of solid tumor cancers. Its product lines include DCVax-L, DCVax-Direct, and DCVax-Prostate.
Who founded Northwest Biotherapeutics?
Northwest Biotherapeutics was founded by Alton Boynton.
Who are Northwest Biotherapeutics's investors?
Northwest Biotherapeutics's investors include Vedanta Capital, Yorkville Advisors.
How much funding has Northwest Biotherapeutics raised?
Northwest Biotherapeutics has disclosed $10.9M raised across 3 of its 5 known rounds.
Where is Northwest Biotherapeutics headquartered?
Northwest Biotherapeutics is headquartered in Bethesda, US.